Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor T-cells, are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment. UCART is a therapeutic product line that it is developing with its gene-editing platform to address unmet medical needs in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma and other types of cancers. We show 1 historical shares outstanding datapoints in our CLLS shares outstanding history coverage, used to compute CLLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CLLS market cap history over the course of time is important for investors
interested in comparing CLLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CLLS versus a peer is one thing; comparing
CLLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CLLS can fluctuate over the course of history.
With this page we aim to empower investors researching CLLS by allowing them to research the CLLS market cap history. |
Free CLLS Email Alerts:
Video: The Importance of Market Cap
